uniQure (NASDAQ:QURE) Shares Up 6.6% – Here’s Why

uniQure N.V. (NASDAQ:QURE)’s share price rose 6.6% during mid-day trading on Tuesday . The stock traded as high as $21.93 and last traded at $21.8430. Approximately 802,392 shares changed hands during trading, a decline of 58% from the average daily volume of 1,911,649 shares. The stock had previously closed at $20.50.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure confirmed an upcoming earnings release that may be driving buy interest and short?covering ahead of results. Earnings expectations and any forward guidance will likely be the near?term catalyst investors are trading around. uniQure (QURE) to Release Earnings on Thursday
• Negative Sentiment: A securities?fraud class action was filed alleging investor harm for purchases between Sept. 24 and Oct. 31, 2025 — this directly raises potential legal liability and future costs/settlements. Lead plaintiff motions are due April 13, 2026. Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm
• Negative Sentiment: Multiple plaintiff firms (Kessler Topaz, Rosen, Berger Montague, Levi & Korsinsky, Faruqi & Faruqi, Gross Law, Portnoy, Bernstein Liebhard, ClaimsFiler and others) have filed suits or issued investor alerts seeking class members — the volume of solicitations increases the probability of consolidated litigation and associated legal costs. NASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against uniQure N.V.
• Negative Sentiment: Investor?targeted reminders (including notices for investors with losses >$100k) keep the litigation story in public view and may pressure sentiment if quarterly results or disclosures fail to address the alleged issues. Lead?plaintiff deadline: April 13, 2026. uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. – QURE

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on QURE. Chardan Capital reissued a “buy” rating and issued a $53.00 price objective on shares of uniQure in a research report on Thursday, December 4th. Leerink Partners lowered their price target on shares of uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Mizuho cut their price objective on shares of uniQure from $60.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, December 8th. Stifel Nicolaus reduced their price objective on uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of uniQure in a research report on Tuesday, February 10th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $58.33.

uniQure Trading Up 4.1%

The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -5.56 and a beta of 0.66. The business’s 50-day moving average price is $23.52 and its two-hundred day moving average price is $29.26.

Insiders Place Their Bets

In related news, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the transaction, the director owned 20,439 shares in the company, valued at approximately $557,575.92. This trade represents a 23.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the sale, the director directly owned 32,342 shares of the company’s stock, valued at $796,260.04. This represents a 44.19% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Private Trust Co. NA acquired a new position in shares of uniQure during the 3rd quarter worth $28,000. Torren Management LLC bought a new position in uniQure in the fourth quarter valued at about $28,000. Jones Financial Companies Lllp grew its position in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares during the last quarter. IFP Advisors Inc acquired a new position in uniQure during the fourth quarter worth about $48,000. Finally, Smartleaf Asset Management LLC bought a new position in shares of uniQure in the fourth quarter worth about $48,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.